Mert Kilic1, Metin Vural2, Bilgen Coskun2, Ömer Acar3, Yesim Saglican4, Sergin Akpek2, Tarik Esen5. 1. Department of Urology, VKF American Hospital, Istanbul, Turkey. 2. Department of Radiology, VKF American Hospital, Istanbul, Turkey. 3. Department of Urology, Koç University, School of Medicine, Istanbul, Turkey. 4. Department of Pathology, VKF American Hospital, Istanbul, Turkey. 5. Department of Urology, VKF American Hospital, Istanbul, Turkey; Department of Urology, Koç University, School of Medicine, Istanbul, Turkey. Electronic address: TESEN@ku.edu.tr.
Abstract
BACKGROUND: Targeting multiparametric magnetic resonance imaging (MP-MRI)-suspicious regions alone in biopsy-naive patients is not common practice, since it may miss clinically significant prostate cancer (PCa). OBJECTIVE: To investigate the accuracy of in-bore MRI-guided biopsy of Prostate Imaging Reporting and Data System (PI-RADS) 4 and 5 index lesions alone in biopsy-naive patients undergoing radical prostatectomy (RP). DESIGN, SETTING, AND PARTICIPANTS: A total of 170 patients underwent MRI-guided in-bore biopsy for PI-RADS 4 and 5 index lesions alone between 2013 and 2018, of whom 136 patients were diagnosed with PCa. Fifty-two patients without prior biopsy who underwent RP were included in this study. MP-MRI findings, biopsy results, and whole-mount step-section specimen evaluation were retrospectively analyzed. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Continuous variables were reported as mean (standard deviation) or median (range). Differences in parametric variables were calculated by Student t test. RESULTS AND LIMITATIONS: Overall International Society of Urological Pathology grade group (GG) up- and downgrading rates were 23.0% and 7.6% per patient and 24.5% and 6.5% per focus, respectively. Ten of 12 biopsy-detected GG 1 foci were upgraded in the final pathology. In 30 patients, a total of 43 different tumor foci were identified outside the sampled index lesion. Average biopsied and nonbiopsied tumor volumes were found to be 2.02 and 0.45 cm³, respectively (p < 0.001). The index lesion was the largest focus of tumor in all patients' final histopathological examination; upgrading was identified in only one nonbiopsied focus in a single patient. Limitations include retrospective design and nonstandard indications of in-bore MRI biopsy. CONCLUSIONS: In-bore MRI-guided biopsy of PI-RADS 4-5 index lesions alone in biopsy-naive patients is a safe and accurate diagnostic modality allowing appropriate patient selection for individualized treatment. PATIENT SUMMARY: In-bore magnetic resonance imaging-guided prostate biopsy of suspicious lesions alone allows accurate risk stratification of patients and reduces the detection of insignificant prostate cancer.
BACKGROUND: Targeting multiparametric magnetic resonance imaging (MP-MRI)-suspicious regions alone in biopsy-naive patients is not common practice, since it may miss clinically significant prostate cancer (PCa). OBJECTIVE: To investigate the accuracy of in-bore MRI-guided biopsy of Prostate Imaging Reporting and Data System (PI-RADS) 4 and 5 index lesions alone in biopsy-naive patients undergoing radical prostatectomy (RP). DESIGN, SETTING, AND PARTICIPANTS: A total of 170 patients underwent MRI-guided in-bore biopsy for PI-RADS 4 and 5 index lesions alone between 2013 and 2018, of whom 136 patients were diagnosed with PCa. Fifty-two patients without prior biopsy who underwent RP were included in this study. MP-MRI findings, biopsy results, and whole-mount step-section specimen evaluation were retrospectively analyzed. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Continuous variables were reported as mean (standard deviation) or median (range). Differences in parametric variables were calculated by Student t test. RESULTS AND LIMITATIONS: Overall International Society of Urological Pathology grade group (GG) up- and downgrading rates were 23.0% and 7.6% per patient and 24.5% and 6.5% per focus, respectively. Ten of 12 biopsy-detected GG 1 foci were upgraded in the final pathology. In 30 patients, a total of 43 different tumor foci were identified outside the sampled index lesion. Average biopsied and nonbiopsied tumor volumes were found to be 2.02 and 0.45 cm³, respectively (p < 0.001). The index lesion was the largest focus of tumor in all patients' final histopathological examination; upgrading was identified in only one nonbiopsied focus in a single patient. Limitations include retrospective design and nonstandard indications of in-bore MRI biopsy. CONCLUSIONS: In-bore MRI-guided biopsy of PI-RADS 4-5 index lesions alone in biopsy-naive patients is a safe and accurate diagnostic modality allowing appropriate patient selection for individualized treatment. PATIENT SUMMARY: In-bore magnetic resonance imaging-guided prostate biopsy of suspicious lesions alone allows accurate risk stratification of patients and reduces the detection of insignificant prostate cancer.
Authors: Martina Gurgitano; Eleonora Ancona; Duilia Maresca; Paul Eugene Summers; Sarah Alessi; Roberta Maggioni; Alessandro Liguori; Marco Pandolfi; Giovanni Maria Rodà; Massimo De Filippo; Aldo Paolucci; Giuseppe Petralia Journal: Acta Biomed Date: 2020-09-23